David E. Gerber, MD

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.

Improving diversity in cancer clinical trial enrollment has become an increased priority among oncology researchers.